Skip to content Skip to footer
Subscribe Now
Viewpoints_Brady Granier
VIEWPOINTS

PharmaShots Interview: BioCorRx’ Brady Granier Shares Insights on the New Agreement with Recro to Support BICX104

In an interview with PharmaShots, Brady Granier, CEO, President, and Director at BioCorRx shared his views on the companies existing collaboration & expands with the signing of a new development and manufacturing agreement to support BICX104 for opioid use disorderShots:The companies have expanded an ongoing collaboration by signing a new development and manufacturing agreement to support BICX104 for…
November 2, 2021

Read more

Viewpoints_Txema Sanz
VIEWPOINTS

PharmaShots Interview: Astellas’ Txema Sanz Shares Insights on the Evrenzo (roxadustat) for Symptomatic Anemia Associated with Chronic Kidney Disease

In an interview with PharmaShots, Txema Sanz, Senior Vice President and Head of the Global Medical Specialties at Astellas shared his views on the EC's approval of Evrenzo (roxadustat) for the Treatment of symptomatic anemia associated with Chronic Kidney DiseaseShots:The approval is based on the P-III program including 8 studies evaluating Evrenzo in 9600 patients with symptomatic anemia associated with…
October 27, 2021

Read more

Viewpoints_Dr. Robert Koenekoop
VIEWPOINTS

PharmaShots Interview: Dr. Robert Koenekoop Shares Insights on Stellar Study Evaluating ProQR’s QR-421a

In an interview with PharmaShots, Dr. Robert Koenekoop, MD, PhD, Professor of Pediatric Surgery, Human Genetics and Adult Ophthalmology at McGill University's Montreal Children's Hospital shared his views on the clinical data of the trial and shed light on how RNA therapies work in eye disorders?Shots:QR-421a demonstrated a concordant benefit in multiple measures of vision…
May 3, 2021

Read more

Viewpoints_Dr. Todd D. Cohen
VIEWPOINTS

PharmaShots Interview: Myriad Genetics’ Dr. Todd D. Cohen Shares Insight on Prolaris Test’s Ability to Guide Prostate Cancer Treatment

In an interview with PharmaShots, Dr. Todd D. Cohen, M.D., VP Medical Affairs and Medical Director of Urology at Myriad Genetics shared his views on the ability of a biomarker test to predict which men with aggressive prostate cancer will benefit from advanced hormonal therapy and which men with lower-risk prostate cancer can safely avoid such treatments.…
March 25, 2021

Read more

Viewpoint_Lotus Mallbris_2020
VIEWPOINTS

PharmaShots Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insights on Baricitinib

In a recent interview with PharmaShots, Dr. Lotus Mallbris, the Vice President of Immunology Development at Eli Lilly shares her insights and highlights on Baricitinib.Shots:If approved, Baricitinib could be the first JAK inhibitor in the EU for adults with moderate to severe AD. EC's decision is expected in the next one-two months.Lilly is evaluating Baricitinib for SLE, for which…
October 12, 2020

Read more

Viewpoint_Ted Omachi_2020
VIEWPOINTS

PharmaShots Interview: Genentech’s Ted Omachi Shares Insights on Xolair (omalizumab) PFS

The US FDA has accepted the sBLA for a new self-administration option for Xolair (omalizumab) across all approved US indications.In an interview with PharmaShots, Ted Omachi the Global Development Leader for Xolair and Senior Medical Director of Product Development Immunology shares details and highlights of Xolair (omalizumab) PFS for self-administration.Shots:A decision on…
September 7, 2020

Read more